|
1
|
Huang J, Hao P, Zhang YL, Deng FX, Deng Q,
Hong Y, Wang XW, Wang Y, Li TT, Zhang XG, et al: Discovering
multiple transcripts of human hepatocytes using massively parallel
signature sequencing (MPSS). BMC Genomics. 8:2072007.
|
|
2
|
Plaz Torres MC, Bodini G, Furnari M,
Marabotto E, Zentilin P, Strazzabosco M and Giannini EG:
Surveillance for hepatocellular carcinoma in patients with
non-alcoholic fatty liver disease: universal or selective? Cancers
(Basel). 12:14222020.
|
|
3
|
He T, Wang L, Gou S, Lu L, Liu G, Wang K,
Yang Y, Duan Q, Geng W, Zhao P, et al: Enhanced immunogenic cell
death and antigen presentation via engineered bifidobacterium
bifidum to boost chemo-immunotherapy. ACS Nano. 17:9953–9971.
2023.
|
|
4
|
Lu Q, Huang H, Wang X, Luo L, Xia H, Zhang
L, Xu J, Huang Y, Luo X and Luo J: Echinatin inhibits the growth
and metastasis of human osteosarcoma cells through Wnt/β-catenin
and p38 signaling pathways. Pharmacol Res. 191:1067602023.
|
|
5
|
Vanmeerbeek I, Sprooten J, De Ruysscher D,
Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer
G, Galluzzi L, et al: Trial watch: Chemotherapy-induced immunogenic
cell death in immuno-oncology. Oncoimmunology. 9:17034492020.
|
|
6
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia
GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T,
Casares N, et al: Calreticulin exposure dictates the immunogenicity
of cancer cell death. Nat Med. 13:54–61. 2007.
|
|
7
|
Green DR, Ferguson T, Zitvogel L and
Kroemer G: Immunogenic and tolerogenic cell death. Nat Rev Immunol.
9:353–363. 2009.
|
|
8
|
Casares N, Pequignot MO, Tesniere A,
Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs
S, Obeid M, et al: Caspase-dependent immunogenicity of
doxorubicin-induced tumor cell death. J Exp Med. 202:1691–1701.
2005.
|
|
9
|
Birmpilis AI, Paschalis A, Mourkakis A,
Christodoulou P, Kostopoulos IV, Antimissari E, Terzoudi G,
Georgakilas AG, Armpilia C, Papageorgis P, et al: Immunogenic cell
death, DAMPs and prothymosin α as a putative anticancer immune
response biomarker. Cells. 11:14152022.
|
|
10
|
Zhai J, Gu X, Liu Y, Hu Y, Jiang Y and
Zhang Z: Chemotherapeutic and targeted drugs-induced immunogenic
cell death in cancer models and antitumor therapy: An update
review. Front Pharmacol. 14:11529342023.
|
|
11
|
Shi Y, Hou X, Yu S, Pan X, Yang M, Hu J
and Wang X: Targeted delivery of doxorubicin into tumor cells to
decrease the in vivo toxicity of glutathione-sensitive
prodrug-poloxamer188-b-polycaprolactone nanoparticles and improve
their anti-tumor activities. Colloids Surf B Biointerfaces.
220:1128742022.
|
|
12
|
Wu PJ, Chiou HL, Hsieh YH, Lin CL, Lee HL,
Liu IC and Ying TH: Induction of immunogenic cell death effect of
licoricidin in cervical cancer cells by enhancing endoplasmic
reticulum stress-mediated high mobility group box 1 expression.
Environ Toxicol. 38:1641–1650. 2023.
|
|
13
|
Aria H and Rezaei M: Immunogenic cell
death inducer peptides: A new approach for cancer therapy, current
status and future perspectives. Biomed Pharmacother.
161:1145032023.
|
|
14
|
Lu Y, Sun W, Du J, Fan J and Peng X:
Immuno-photodynamic therapy (IPDT): Organic photosensitizers and
their application in cancer ablation. JACS Au. 3:682–699. 2023.
|
|
15
|
Shimabukuro-Vornhagen A, Draube A, Liebig
TM, Rothe A, Kochanek M and von Bergwelt-Baildon MS: The
immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the
antigen-presenting function of CD40-activated B cells. J Exp Clin
Cancer Res. 31:472012.
|
|
16
|
Fan X, Jin J, Yan L, Liu L, Li Q and Xu Y:
The impaired anti-tumoral effect of immune surveillance cells in
the immune microenvironment of gastric cancer. Clin Immunol.
219:1085512020.
|
|
17
|
Dai Z, Tang J, Gu Z, Wang Y, Yang Y, Yang
Y and Yu C: Eliciting immunogenic cell death via a unitized
nanoinducer. Nano Lett. 20:6246–6254. 2020.
|
|
18
|
Wu H, Wei G, Luo L, Li L, Gao Y, Tan X,
Wang S, Chang H, Liu Y, Wei Y, et al: Ginsenoside Rg3 nanoparticles
with permeation enhancing based chitosan derivatives were
encapsulated with doxorubicin by thermosensitive hydrogel and
anti-cancer evaluation of peritumoral hydrogel injection combined
with PD-L1 antibody. Biomater Res. 26:772022.
|
|
19
|
Yu Z, Guo J, Hu M, Gao Y and Huang L:
Icaritin exacerbates mitophagy and synergizes with doxorubicin to
induce immunogenic cell death in hepatocellular carcinoma. ACS
Nano. 14:4816–4828. 2020.
|
|
20
|
Zeng Y, Wang J, Huang Q, Ren Y, Li T,
Zhang X, Yao R and Sun J: Cucurbitacin IIa: A review of
phytochemistry and pharmacology. Phytother Res. 35:4155–4170.
2021.
|
|
21
|
Peng Y, Chen T, Luo L, Li L, Cao W, Xu X,
Zhang Y, Yue P, Dai X, Ji Z, et al: Isoforskolin and cucurbitacin
IIa promote the expression of anti-inflammatory regulatory factor
SIGIRR in human macrophages stimulated with Borrelia burgdorferi
basic membrane protein A. Int Immunopharmacol. 88:1069142020.
|
|
22
|
Singh N, Krishnakumar S, Kanwar RK, Cheung
CH and Kanwar JR: Clinical aspects for survivin: A crucial molecule
for targeting drug-resistant cancers. Drug Discov Today.
20:578–587. 2015.
|
|
23
|
Zhang J, Song Y, Liang Y, Zou H, Zuo P,
Yan M, Jing S, Li T, Wang Y, Li D, et al: Cucurbitacin IIa
interferes with EGFR-MAPK signaling pathway leads to proliferation
inhibition in A549 cells. Food Chem Toxicol. 132:1106542019.
|
|
24
|
Boykin C, Zhang G, Chen YH, Zhang RW, Fan
XE, Yang WM and Lu Q: Cucurbitacin IIa: a novel class of
anti-cancer drug inducing non-reversible actin aggregation and
inhibiting survivin independent of JAK2/STAT3 phosphorylation. Br J
Cancer. 104:781–789. 2011.
|
|
25
|
Yu K, Yang X, Li Y, Cui X, Liu B and Yao
Q: Synthesis of cucurbitacin IIa derivatives with
apoptosis-inducing capabilities in human cancer cells. RSC Adv.
10:3872–3881. 2020.
|
|
26
|
Kuang Z, Wu J, Tan Y, Zhu G, Li J and Wu
M: MicroRNA in the diagnosis and treatment of doxorubicin-induced
cardiotoxicity. Biomolecules. 13:5682023.
|
|
27
|
Yu S, Cai X, Wu C, Liu Y, Zhang J, Gong X,
Wang X, Wu X, Zhu T, Mo L, et al: Targeting HSP90-HDAC6 regulating
network implicates precision treatment of breast cancer. Int J Biol
Sci. 13:505–517. 2017.
|
|
28
|
O'Donohue TJ, Ibáñez G, Coutinho DF,
Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long
M, et al: Translational strategies for repotrectinib in
neuroblastoma. Mol Cancer Ther. 20:2189–2197. 2021.
|
|
29
|
Bhagat A and Kleinerman ES:
Anthracycline-induced cardiotoxicity: Causes, mechanisms, and
prevention. Adv Exp Med Biol. 1257:181–192. 2020.
|
|
30
|
Ma X, Yang S, Zhang T, Wang S, Yang Q,
Xiao Y, Shi X, Xue P, Kang Y, Liu G, et al: Bioresponsive
immune-booster-based prodrug nanogel for cancer immunotherapy. Acta
Pharm Sin B. 12:451–466. 2022.
|
|
31
|
Bao L, Hao C, Wang J, Wang D, Zhao Y, Li Y
and Yao W: High-dose cyclophosphamide administration orchestrates
phenotypic and functional alterations of immature dendritic cells
and regulates Th cell polarization. Front Pharmacol.
11:7752020.
|
|
32
|
Shan Z, Wang H, Zhang Y and Min W: The
role of tumor-derived exosomes in the abscopal effect and
immunotherapy. Life (Basel). 11:3812021.
|
|
33
|
Deng Z, Zhang M, Zhu T, Zhili N, Liu Z,
Xiang R, Zhang W and Xu Y: Dynamic changes in peripheral blood
lymphocyte subsets in adult patients with COVID-19. Int J Infect
Dis. 98:353–358. 2020.
|
|
34
|
Yu H, Zou W, Mi C, Wang Q, Dai G, Zhang T,
Zhang G, Xie K, Wang J and Shi H: Research Note: Expression of T
cell-related cytokines in chicken cecal and spleen tissues
following Eimeria tenella infection in vivo. Poult Sci.
100:1011612021.
|
|
35
|
Sasidharan Nair V, Saleh R, Toor SM, Taha
RZ, Ahmed AA, Kurer MA, Murshed K, Alajez NM, Abu Nada M and Elkord
E: Transcriptomic profiling disclosed the role of DNA methylation
and histone modifications in tumor-infiltrating myeloid-derived
suppressor cell subsets in colorectal cancer. Clin Epigenetics.
12:132020.
|
|
36
|
Wellenstein MD and de Visser KE:
Cancer-cell-intrinsic mechanisms shaping the tumor immune
landscape. Immunity. 48:399–416. 2018.
|
|
37
|
Si W, Lyu J, Liu Z, Wang C, Huang J, Jiang
L and Ma T: Cucurbitacin E inhibits cellular proliferation and
enhances the chemo-response in gastric cancer by suppressing AKt
activation. J Cancer. 10:5843–5851. 2019.
|
|
38
|
Yin S, Mai Z, Liu C, Xu L and Xia C:
Label-free-based quantitative proteomic analysis of the inhibition
of cisplatin-resistant ovarian cancer cell proliferation by
cucurbitacin B. Phytomedicine. 111:1546692023.
|
|
39
|
Ni K, Lan G, Guo N, Culbert A, Luo T, Wu
T, Weichselbaum RR and Lin W: Nanoscale metal-organic frameworks
for x-ray activated in situ cancer vaccination. Sci Adv.
6:eabb52232020.
|
|
40
|
Sun D, Zou Y, Song L, Han S, Yang H, Chu
D, Dai Y, Ma J, O'Driscoll CM, Yu Z and Guo J: A cyclodextrin-based
nanoformulation achieves co-delivery of ginsenoside Rg3 and
quercetin for chemo-immunotherapy in colorectal cancer. Acta Pharm
Sin B. 12:378–393. 2022.
|
|
41
|
Yang Q, Shi G, Chen X, Lin Y, Cheng L,
Jiang Q, Yan X, Jiang M, Li Y, Zhang H, et al: Nanomicelle protects
the immune activation effects of Paclitaxel and sensitizes tumors
to anti-PD-1 immunotherapy. Theranostics. 10:8382–8399. 2020.
|
|
42
|
Wu Q, Li B, Li J and Sun S, Yuan J and Sun
S: Cancer-associated adipocytes as immunomodulators in cancer.
Biomark Res. 9:22021.
|
|
43
|
Szczygieł A, Węgierek-Ciura K, Wróblewska
A, Mierzejewska J, Rossowska J, Szermer-Olearnik B, Świtalska M,
Anger-Góra N, Goszczyński TM and Pajtasz-Piasecka E: Combined
therapy with methotrexate nanoconjugate and dendritic cells with
downregulated IL-10R expression modulates the tumor
microenvironment and enhances the systemic anti-tumor immune
response in MC38 murine colon carcinoma. Front Immunol.
14:11553772023.
|
|
44
|
Evgin L and Vile RG: Parking CAR T cells
in tumours: Oncolytic viruses as valets or vandals? Cancers
(Basel). 13:11062021.
|
|
45
|
Li J, Zhao M, Liang W, Wu S, Wang Z and
Wang D: Codelivery of Shikonin and siTGF-β for enhanced triple
negative breast cancer chemo-immunotherapy. J Control Release.
342:308–320. 2022.
|
|
46
|
Shao Y, Lo CM, Ling CC, Liu XB, Ng KTP,
Chu ACY, Ma YY, Li CX, Fan ST and Man K: Regulatory B cells
accelerate hepatocellular carcinoma progression via CD40/CD154
signaling pathway. Cancer Lett. 355:264–272. 2014.
|
|
47
|
Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu
F, Cheung OKW, Sun H, Zeng X, Tang W, et al: Targeting
monocyte-intrinsic enhancer reprogramming improves immunotherapy
efficacy in hepatocellular carcinoma. Gut. 69:365–379. 2020.
|
|
48
|
He F, Furones AR, Landegren N, Fuxe J and
Sarhan D: Sex dimorphism in the tumor microenvironment-from bench
to bedside and back. Semin Cancer Biol. 86:166–179. 2022.
|
|
49
|
He J, Wang Y, Xu LH, Qiao J, Ouyang DY and
He XH: Cucurbitacin IIa induces caspase-3-dependent apoptosis and
enhances autophagy in lipopolysaccharide-stimulated RAW 264.7
macrophages. Int Immunopharmacol. 16:27–34. 2013.
|
